超声造影在肝细胞癌局部精准诊疗全流程管理中的应用
DOI: 10.12449/JCH260705
利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:周燕负责撰写文章;经翔负责拟定写作思路;丁建民、经翔负责指导撰写文章并最终定稿。
Application of contrast-enhanced ultrasound in the full-course management of precise locoregional diagnosis and treatment for hepatocellular carcinoma
-
摘要: 肝细胞癌(HCC)是我国疾病负担最为沉重的恶性肿瘤之一,多数患者确诊时已丧失根治性手术切除机会,局部介入治疗在HCC全程管理中的重要性日益提升。超声造影(CEUS)可实时、动态显示肿瘤微循环灌注特征,并具备床旁可用性、无电离辐射及可重复性等优势,其应用已从辅助诊断扩展至HCC精准局部诊疗的全流程管理。治疗前,CEUS可用于病灶的定性诊断、定位、活性范围评估及穿刺路径规划,提升常规超声显示不清病灶的辨识度;治疗中及治疗后,CEUS能够及时检测残余活性病灶、相关并发症及局部肿瘤进展,为补充消融、经导管动脉化疗栓塞或联合治疗策略的调整提供依据。CEUS肝脏影像报告和数据系统的治疗反应评估体系的建立,为局部治疗后疗效评价提供了标准化方案;同时,单模态及多模态融合影像技术的发展促进了CEUS在HCC精准局部诊疗中的规范化应用。随着对消融安全边界的进一步重视,局部消融疗效评价的核心已从“是否实现影像学完全消融”转向“无造影、不消融,无融合、不根治”的新治疗理念。本文围绕CEUS在HCC局部介入诊疗中的技术优势、临床应用价值、治疗反应评价、融合影像拓展及当前局限性展开述评,以期为HCC的个体化与精准化管理提供参考。Abstract: Hepatocellular carcinoma (HCC) is one of the major malignancies with the heaviest disease burden in China. Many patients have lost the opportunity for radical surgical resection at the time of diagnosis, with locoregional interventional therapy playing an increasingly important role in full-course HCC management. Contrast-enhanced ultrasound (CEUS) enables real-time dynamic assessment of tumor microvascular perfusion and has several practical advantages including bedside availability, no ionizing radiation, and repeatability, and its role has therefore expanded from an adjunctive diagnostic method to the full-course management of precise locoregional diagnosis and treatment for HCC. Before treatment, CEUS can assist in the qualitative diagnosis of lesions, lesion localization, delineation of the viable tumor, and planning of the puncture route, especially for lesions that are poorly visualized on conventional ultrasound. During and after treatment, CEUS can help to detect residual viable tumor, related complications, and local tumor progression, thereby providing a basis for additional ablation, transcatheter arterial chemoembolization, or adjustment of combined treatment strategies. In recent years, the CEUS LI-RADS treatment response assessment system has provided a standardized framework for evaluating response after locoregional therapy, and in addition, the development of unimodal and multimodal fusion imaging techniques has further promoted the standardized application of CEUS in precise locoregional therapy for HCC. As increasing attention is paid to the ablation margin, the goal of response evaluation for local ablation has shifted from “the achievement of imaging-defined complete ablation” to a new treatment paradigm of “no contrast-enhanced imaging, no ablation; no fusion imaging, no curative ablation”. This article reviews the technical advantages, clinical application value, treatment response assessment, fusion imaging strategies, and current limitations of CEUS in locoregional interventional diagnosis and treatment of HCC, in order to provide a reference for the individualized and precise management of HCC.
-
Key words:
- Carcinoma, Hepatocellular /
- Ultrasonography /
- Precision Medicine /
- Clinical Governance
-
[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74( 3): 229- 263. DOI: 10.3322/caac.21834. [2] Chhikara B S, Parang K. Global Cancer Statistics 2022: the trends projection analysis[M]. Chem Biol Lett, 2023, 10( 1): 451. [3] Zeng H M, Zheng R S, Sun K X, et al. Cancer survival statistics in China 2019–2021: A multicenter, population-based study[J]. J Natl Cancer Cent, 2024, 4( 3): 203- 213. DOI: 10.1016/j.jncc.2024.06.005. [4] Tan E Y, Danpanichkul P, Yong J N, et al. Liver cancer in 2021: Global burden of disease study[J]. J Hepatol, 2025, 82( 5): 851- 860. DOI: 10.1016/j.jhep.2024.10.031. [5] Han B F, Zheng R S, Zeng H M, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4( 1): 47- 53. DOI: 10.1016/j.jncc.2024.01.006. [6] Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update[J]. J Hepatol, 2022, 76( 3): 681- 693. DOI: 10.1016/j.jhep.2021.11.018. [7] National Health Commission of the People’s Republic of China. Guideline for diagnosis and treatment of primary liver cancer(2026 edition)[J]. J Clin Hepatol, 2026, 42( 4): 794- 827. DOI: 10.12449/JCH260409.中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2026年版)[J]. 临床肝胆病杂志, 2026, 42( 4): 794- 827. DOI: 10.12449/JCH260409. [8] Yang Y, Yu H L, Qi L Y, et al. Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: A systematic review and meta-analysis[J]. Int J Hyperthermia, 2022, 39( 1): 455- 465. DOI: 10.1080/02656736.2022.2048095. [9] Ding J M, Long L, Zhang X, et al. Contrast-enhanced ultrasound LI-RADS 2017: Comparison with CT/MRI LI-RADS[J]. Eur Radiol, 2021, 31( 2): 847- 854. DOI: 10.1007/s00330-020-07159-z. [10] Zhou Y, Qin Z Y, Ding J M, et al. Risk stratification and distribution of hepatocellular carcinomas in CEUS and CT/MRI LI-RADS: A meta-analysis[J]. Front Oncol, 2022, 12: 873913. DOI: 10.3389/fonc.2022.873913. [11] Qiu S B, Ding J M, Wang Y D, et al. Dynamic contrast-enhanced ultrasonography combined with LR-M classification criteria for differentiating malignant liver nodules at high risk for hepatocellular carcinoma[J]. Ultrasound Med Biol, 2024, 50( 7): 1028- 1033. DOI: 10.1016/j.ultrasmedbio.2024.03.016. [12] Badiu S M, Gheorghe E C, Nicolau C, et al. Quantitative time intensity curve analysis of contrast-enhanced ultrasound(CEUS) examinations for the assessment of focal liver lesions[J]. Med Ultrason, 2024, 26( 1): 63- 71. DOI: 10.11152/mu-4108. [13] Ying X Q, Dong S X, Zhao Y Y, et al. Research progress on contrast-enhanced ultrasound(CEUS) assisted diagnosis and treatment in liver-related diseases[J]. Int J Med Sci, 2025, 22( 5): 1092- 1108. DOI: 10.7150/ijms.101789. [14] Qin Z, Zhou Y, Ding J, et al. Risk stratification for hepatocellular carcinoma of contrast-enhanced ultrasound Liver Imaging Reporting and Data System(LI-RADS) and the diagnostic performance of LR-5 and LR-M: A systematic review and meta-analysis[J]. Clin Radiol, 2022, 77( 4): e280- e286. DOI: 10.1016/j.crad.2022.01.041. [15] Park J H, Park M S, Lee S J, et al. Contrast-enhanced US with perfluorobutane for hepatocellular carcinoma surveillance: A multicenter diagnostic trial(SCAN)[J]. Radiology, 2019, 292( 3): 638- 646. DOI: 10.1148/radiol.2019190183. [16] Meloni M F, Francica G, Chiang J, et al. Use of contrast-enhanced ultrasound in ablation therapy of HCC: Planning, guiding, and assessing treatment response[J]. J Ultrasound Med, 2021, 40( 5): 879- 894. DOI: 10.1002/jum.15471. [17] Wang F H, Zhang Q, Yan K, et al. 3D-CEUS/MRI–CEUS fusion imaging vs 2D-CEUS after locoregional therapies for hepatocellular carcinoma: A multicenter prospective study of therapeutic responseevaluation[J]. Eur Radiol, 2025, 35( 1): 453- 462. DOI: 10.1007/s00330-024-10915-0. [18] Kim Y R, Kim E, Kim H I, et al. Updated network meta-analysis of first-line systemic treatments for advanced HCC: Consistent role of TACE[J]. Liver Cancer, 2026, 15( 1): 117- 134. DOI: 10.1159/000546697. [19] Zhou Hongyu, Zhou Yan, Ding Jianmin, et al. Long term outcome of combining transarterial chemoembolization and radiofrequency ablation therapy for large hepatocellular carcinoma[J/OL]. Chin J Med Ultrasound Electron Ed, 2018, 15( 9): 700- 706. DOI: 10.3877/cma.j.issn.1672-6448.2018.09.011.周洪雨, 周燕, 丁建民, 等. 肝动脉化疗栓塞联合射频消融治疗直径≥5 cm肝细胞癌患者10年疗效及预后分析[J/OL]. 中华医学超声杂志(电子版), 2018, 15( 9): 700- 706. DOI: 10.3877/cma.j.issn.1672-6448.2018.09.011. [20] Lyshchik A, Fetzer D T, Kono Y, et al. Liver imaging reporting and data system contrast-enhanced US nonradiation treatment response assessment version 2024[J]. Radiology, 2024, 311( 2): e232369. DOI: 10.1148/radiol.232369. [21] Yao J Q, Guo H L, Zhang X E, et al. Local tumor progression after hepatocellular carcinoma ablation: CEUS LI-RADS nonradiation TRA version 2024 versus a modified algorithm[J]. Ultrasound Med Biol, 2026, 52( 6): 1116- 1124. DOI: 10.1016/j.ultrasmedbio.2026.02.012. [22] Kuon Yeng Escalante C M, Siu Xiao T, Nagaraj R U, et al. Evaluation of the contrast-enhanced ultrasound nonradiation treatment response assessment LI-RADS v2024 using data from a multi-center transarterial chemoembolization study[J]. Acad Radiol, 2024, 31( 12): 5078- 5086. DOI: 10.1016/j.acra.2024.06.005. [23] Ding J M, Wang D, Zhou Y, et al. A novel mono-modality fusion imaging method based on three-dimensional contrast-enhanced ultrasound for the evaluation of ablation margins after microwave ablation of hepatocellular carcinoma[J]. J Gastrointest Oncol, 2021, 12( 1): 184- 195. DOI: 10.21037/jgo-21-46. [24] Zhou Y, Wang Y D, Wang F M, et al. Additional diagnostic value of fusion imaging of CEUS and first CEUS of invisible hepatic lesions ≤2 cm[J]. J Ultrasound Med, 2021, 40( 6): 1173- 1181. DOI: 10.1002/jum.15498. [25] Lee Y, Yoon J H, Han S, et al. Contrast-enhanced ultrasonography-CT/MRI fusion guidance for percutaneous ablation of inconspicuous, small liver tumors: Improving feasibility and therapeutic outcome[J]. Cancer Imaging, 2024, 24( 1): 4. DOI: 10.1186/s40644-023-00650-y. [26] Zhang X D, He X Q, Zeng Q J, et al. Utility of fusion imaging for percutaneous thermal ablation of hepatocellular carcinoma in the caudate lobe[J]. J Vasc Interv Radiol, 2021, 32( 8): 1209- 1214. DOI: 10.1016/j.jvir.2021.04.028. [27] You Y J, Long Y L, Yan R H, et al. Improving ablation safety for hepatocellular carcinoma proximal to the hilar bile ducts by ultrasound-MR fusion imaging: A preliminary comparative study[J]. Front Oncol, 2021, 11: 570312. DOI: 10.3389/fonc.2021.570312. [28] Luo L P, He X Q, Li K, et al. Thermal ablation of medium-sized hepatocellular carcinomas using intraoperative ultrasound fusion imaging: A propensity score-matched analysis[J]. Clin Res Hepatol Gastroenterol, 2021, 45( 5): 101581. DOI: 10.1016/j.clinre.2020.11.011. [29] Liu J M, Guo Y Q, Sun Y T, et al. Three-dimensional ultrasound fusion imaging in precise needle placement for thermal ablation of hepatocellular carcinoma[J]. Int J Hyperthermia, 2024, 41( 1): 2316097. DOI: 10.1080/02656736.2024.2316097. [30] Shiina S, Tateishi R, Choi J I, et al. Asian conference on tumor ablation guidelines for hepatocellular carcinoma[J]. Liver Cancer, 2025, 14( 5): 651- 678. DOI: 10.1159/000544976. [31] Odisio B C, Albuquerque J, Lin Y M, et al. Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation(COVER-ALL): A randomised phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2025, 10( 5): 442- 451. DOI: 10.1016/S2468-1253(25)00024-X. [32] Zhou H Y, Yang G H, Jing X, et al. Predictive value of ablative margin assessment after microwave ablation for local tumor progression in medium and large hepatocellular carcinoma: Computed tomography-computed tomography image fusion method versus side-by-side method[J]. J Comput Assist Tomogr, 2023, 47( 1): 31- 37. DOI: 10.1097/RCT.0000000000001395. [33] Ding W Z, Wu J P, Dou J P, et al. Biologically explicable multimodal model predicting local tumor progression and tumor invasiveness of hepatocellular carcinoma[J]. Hepatology, 2026. DOI: 10.1097/HEP.0000000000001678.[ Online ahead of print] [34] Xu E J, Li K, Long Y L, et al. Intra-procedural CT/MR-ultrasound fusion imaging helps to improve outcomes of thermal ablation for hepatocellular carcinoma: Results in 502 nodules[J]. Ultraschall Med, 2021, 42( 2): e9- e19. DOI: 10.1055/a-1021-1616. [35] Paolucci I, Overduin C G, Johnston E W, et al. International multisociety Delphi consensus for liver tumour thermal ablation: Margin assessment[J]. Lancet Oncol, 2026, 27( 5): e248- e258. DOI: 10.1016/S1470-2045(26)00143-9. [36] Laimer G, Johnston E W, Overduin C G, et al. International multisociety Delphi consensus for liver tumour thermal ablation: procedural and practice standards[J]. Lancet Oncol, 2026, 27( 5): e259- e270. DOI: 10.1016/S1470-2045(26)00114-2. -
本文二维码
计量
- 文章访问数: 5
- HTML全文浏览量: 0
- PDF下载量: 1
- 被引次数: 0

PDF下载 ( 671 KB)
下载:
